TY - JOUR
T1 - Invasive neuroendocrine carcinoma of the breast
T2 - A population-based study from the surveillance, epidemiology and end results (SEER) database
AU - Wang, Jun
AU - Wei, Bing
AU - Albarracin, Constance T.
AU - Hu, Jianhua
AU - Abraham, Susan C.
AU - Wu, Yun
N1 - Funding Information:
The authors wish to thank Kathryn L Hale from the Department of Scientific Publications, The University of Texas MD Anderson Cancer Center, for editorial assistance. Dr. Jun Wang was supported in part by the National Nature Science Foundation of China (grants no. 30901788 and 81272619) and the Shandong Provincial Nature Science Foundation (grants no. ZR2010HQ038 and ZR2010HM059). Dr. Bing Wei was supported in part by the National Nature Science Foundation of China (grant no. 81172536).
PY - 2014/3/4
Y1 - 2014/3/4
N2 - Background: Neuroendocrine carcinoma (NEC) of the breast is a rare type of carcinoma that has not been well studied or characterized. Of the limited number of studies reported in the literature, most are case reports. A few small retrospective series studies have been reported.Methods: We reviewed data on 142 cases of mammary NEC recorded in the surveillance, epidemiology, and end results (SEER) database during 2003-2009 and evaluated disease incidence and patient age, sex, and race/ethnicity; clinicopathologic characteristics; and survival in comparison to invasive mammary carcinoma, not otherwise specified. We also performed univariate and multivariate analyses to identify prognostic factors in this disease.Results: Review of the 142 SEER cases revealed that NEC is an aggressive variant of invasive mammary carcinoma. It generally occurred in older women (>60 years); present with larger tumor size (>20 mm), higher histologic grade, and higher clinical stage; and result in shorter overall survival and disease-specific survival than invasive mammary carcinoma, not otherwise specified (IMC-NOS). Overall survival and disease-specific survival were shorter in NEC at each stage than in IMC-NOS of the same stage. Furthermore, when all NEC and IMC-NOS cases were pooled together, neuroendocrine differentiation itself was an adverse prognostic factor independent of other known prognostic factors, including age, tumor size, nodal status, histologic grade, estrogen/progesterone receptor status, and therapy.Conclusions: NEC is a rare but aggressive type of mammary carcinoma. Novel therapeutic approaches should be explored for this uniquely clinical entity.
AB - Background: Neuroendocrine carcinoma (NEC) of the breast is a rare type of carcinoma that has not been well studied or characterized. Of the limited number of studies reported in the literature, most are case reports. A few small retrospective series studies have been reported.Methods: We reviewed data on 142 cases of mammary NEC recorded in the surveillance, epidemiology, and end results (SEER) database during 2003-2009 and evaluated disease incidence and patient age, sex, and race/ethnicity; clinicopathologic characteristics; and survival in comparison to invasive mammary carcinoma, not otherwise specified. We also performed univariate and multivariate analyses to identify prognostic factors in this disease.Results: Review of the 142 SEER cases revealed that NEC is an aggressive variant of invasive mammary carcinoma. It generally occurred in older women (>60 years); present with larger tumor size (>20 mm), higher histologic grade, and higher clinical stage; and result in shorter overall survival and disease-specific survival than invasive mammary carcinoma, not otherwise specified (IMC-NOS). Overall survival and disease-specific survival were shorter in NEC at each stage than in IMC-NOS of the same stage. Furthermore, when all NEC and IMC-NOS cases were pooled together, neuroendocrine differentiation itself was an adverse prognostic factor independent of other known prognostic factors, including age, tumor size, nodal status, histologic grade, estrogen/progesterone receptor status, and therapy.Conclusions: NEC is a rare but aggressive type of mammary carcinoma. Novel therapeutic approaches should be explored for this uniquely clinical entity.
KW - Breast
KW - Endocrine carcinoma
KW - Invasive carcinoma
KW - Neuroendocrine carcinoma
KW - SEER registry
UR - http://www.scopus.com/inward/record.url?scp=84898600754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898600754&partnerID=8YFLogxK
U2 - 10.1186/1471-2407-14-147
DO - 10.1186/1471-2407-14-147
M3 - Article
C2 - 24589259
AN - SCOPUS:84898600754
SN - 1471-2407
VL - 14
JO - BMC cancer
JF - BMC cancer
IS - 1
M1 - 147
ER -